Highlighting some of the key topics and research published in Bone Marrow Transplantation
Sinusoidal obstruction syndrome (SOS), formerly known as hepatic veno-occlusive disease (VOD) is a serious complication of hematopoietic cell transplantation (HCT). Although it has been described following both autologous and allogenic HCT, it seems much more frequent following the latter, with a reported incidence of 8 to 14%. This can dramatically increase in high risk populations.
From the therapeutic standpoint, defibrotide has been approved recently for the treatment of severe SOS/VOD. The advent of defibrotide has rejuvenated the research in this field of orphan complications after HCT. This web focus collection aims to gather the most recent reports published in the area, with the aim to stimulate interactions and enhance research effort in this field.
Significant advances in the outcome of patients with malignant blood diseases took place over the past decades. For patients with poor-prognosis or relapsed non-Hodgkin lymphoma, Hodgkin disease or multiple myeloma, most treatment protocols include high-dose chemotherapy supported with autologous hematopoietic cell transplantation (ASCT). This however can be envisaged only when mobilized peripheral blood stem cells (PBSC) collection and cryopreservation is successful. In the last few years, the addition of plerixafor – an inhibitor of the interaction between stromal cell-derived factor 1 (SDF-1/CXCL12) and its receptor CXCR4–to G-CSF proved to be an effective modality for PBSC mobilization.
With this background, we have designed this web focus collection dedicated to stem cell mobilization. This collection aims to shed some light on the most recent advances in this field.